Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant (Q39844962)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 21, 2010

Language	Label	Description	Also known as
English	Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant	scientific article published on August 21, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Onchocerca volvulus

object named as

Onchocerca volvulus

1 reference

based on heuristic

inferred from title

9

object named as

Sara Lustigman

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

10

object named as

Shibo Jiang

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

2

object named as

Lanying Du

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

12

object named as

Yusen Zhou

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

4

object named as

Shihui Sun

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

7

object named as

Zhihua Kou

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

3

object named as

Wenjun Xiao

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732469

21 June 2024

author name string

Guangyu Zhao

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Yongping Lin

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Min Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Yuxian He

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Bo-Jian Zheng

11

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

21 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10011941?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.08.049

https://api.crossref.org/works/10.1016/J.VACCINE.2010.08.049

21 June 2024

https://api.elsevier.com/content/article/PII:S0264410X10011941?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.08.049

https://api.crossref.org/works/10.1016/J.VACCINE.2010.08.049

21 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

7233-7240

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Molecular epidemiology of H5N1 avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Jalview Version 2--a multiple sequence alignment editor and analysis workbench

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

H5N1 viruses and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.08.049

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39844962&oldid=2185430347"